Lexaria Bioscience Corp. has expanded its intellectual property portfolio with five newly granted patents across three therapeutic areas, including two patents specifically for diabetes treatment using GLP-1 drugs. The company, which trades on Nasdaq under the symbol LEXX, announced the patent grants resulting from ongoing research and development programs. According to CEO Richard Christopher, the new patents related to diabetes treatments utilizing proprietary technology with already-approved GLP-1 drugs represent a notable achievement given the international race within the GLP-1 industry.
The newly granted patents include two in Japan for compositions and methods for treating hypertension, issued on February 20, 2026, with terms ending on April 25, 2043. These patents, numbered 7823051 and 7823052, belong to Lexaria's patent Family #21, where the company already held three U.S. and one European patent. One Australian patent was granted for compositions and methods for treating epilepsy, issued on February 12, 2026, with a term ending on February 20, 2044. This patent, numbered 2024205127, joins six U.S., one European Union, and four previous Australian patents in Lexaria's patent Family #24.
Most significantly, Lexaria received two Australian patents for compositions and methods for treating diabetes, issued on February 12, 2026, with terms ending on December 3, 2044. These patents, numbered 2025205229 and 2024394427, represent the newest additions to patent Family #27, where Lexaria already held two granted U.S. patents. The company's recent Phase 1b Human Study (GLP-1-H24-4) conducted in Australia provided support in demonstrating the capabilities of its DehydraTECH technology in combination with GLP-1 drugs.
Lexaria's DehydraTECH technology is a patented drug delivery formulation and processing platform that improves how various drugs enter the bloodstream through oral delivery. The technology has demonstrated the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood-brain barrier. The company operates a licensed in-house research laboratory and maintains a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. More information about the company's technology and research can be found at https://www.lexariabioscience.com.
The expansion of Lexaria's patent portfolio has significant implications for the pharmaceutical industry, particularly in the competitive GLP-1 drug market used for diabetes treatment. By securing patents that combine its proprietary DehydraTECH technology with already-approved GLP-1 drugs, Lexaria positions itself as a potential innovator in drug delivery optimization. The company's ongoing research and development projects aim to advance commercial relationships while establishing valuable intellectual property in multiple jurisdictions worldwide. Lexaria expects to receive additional patent awards in the future and will continue reporting on these developments periodically.
For investors and industry observers, the patent grants represent tangible progress in Lexaria's research programs and provide potential competitive advantages in key therapeutic markets. The diabetes treatment patents are particularly relevant given the growing global diabetes epidemic and the expanding market for GLP-1 based therapies. The company's ability to secure patents in multiple international jurisdictions, including Japan and Australia, demonstrates the global applicability of its technology and strengthens its position for potential licensing agreements or partnerships with larger pharmaceutical companies seeking improved drug delivery solutions.
